A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Abstract Background Fragile X syndrome (FXS) is characterized by a range of developmental, neuropsychiatric, and behavioral symptoms that cause significant impairment in those with the disorder. Cannabidiol (CBD) holds promise as a potential treatment for FXS symptoms due to its safety profile and p...

Full description

Bibliographic Details
Main Authors: Helen Heussler, Jonathan Cohen, Natalie Silove, Nancy Tich, Marcel O. Bonn-Miller, Wei Du, Carol O’Neill, Terri Sebree
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Journal of Neurodevelopmental Disorders
Subjects:
Cannabidiol
ZYN002
Zynerba
Transdermal
Fragile X
Pediatric
Online Access:http://link.springer.com/article/10.1186/s11689-019-9277-x

Internet

http://link.springer.com/article/10.1186/s11689-019-9277-x

Similar Items